Black & Veatch Offering Insights to High-Level Presidential Trade and Investment Mission to the Philippines
MANILA, Philippines–(BUSINESS WIRE)–Black & Veatch, a global leader in critical infrastructure solutions, was selected to join the United States... Read more.
Helsinki Airport once again selected as the best airport in Europe
HELSINKI–(BUSINESS WIRE)–Passengers have selected Finland’s Helsinki Airport as the best airport in Europe in terms of customer experience in... Read more.
Hollywood Voices Sound Alarm on Nuclear Threat as Oppenheimer Sweeps the Academy Awards
The Nuclear Threat Initiative’s message about the threat of nuclear weapons blankets Los Angeles as Barbra Streisand, Kristen Stewart and others join the... Read more.
Sprinklr Announces Local Data Hosting Solution in the Kingdom of Saudi Arabia with Google Cloud
NEW YORK–(BUSINESS WIRE)–$CXM #AI—Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises,... Read more.
Epicor Celebrates 30 Years of Driving Innovation and Customer Success Across Asia at Annual Asia Connect Event
BANGKOK–(BUSINESS WIRE)–Epicor, a global industry-specific enterprise software leader, celebrated a multitude of successes at the company’s annual... Read more.
Patient Square Capital, a Leading Health Care-Focused Investment Firm, Agrees to Acquire NanoString Technologies
Binding Agreement to Acquire Substantially All NanoString Assets for $220 Million Pending Bankruptcy Court Approval Agreement Represents Major Step in Financial... Read more.
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
The late-breaking session at the American Academy of Dermatology (AAD) Annual Meeting offers a first look at data from 17 adult and adolescent participants (aged... Read more.
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential... Read more.
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of ruxolitinib cream Results... Read more.
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31 One-year data from an interim analysis... Read more.